Genmab A+s

H. Lundbeck A/s

Crucell Holland B.v.

Genmab Holding B.v.

Janssen Vaccines & Prevention B.v.

Biontech Se

Edward Norbert Van Den Brink

Paul Parren

David Satijn

Rik Rademaker

Ibrahim John Malik

Aran Frank Labrijn

Janine Schuurman

Tom Vink

Pekka Kallunki

Florence Sotty

Karina Fog

Louise Buur Vesterager

Liliana Christina Pereira Montezinho

Jan Van De Winkel

Ann-Louise Bergstrôm

Rob N De Jong

Esther Breij

Dennis Verzijl

Rene Hoet

Joost J Neijssen

Joyce Meesters

Jeffrey B Stavenhagen

Bart De Goeij

Cornelis Adriaan De Kruif

Arnout F Gerritsen

Søren Christensen

Jan Egebjerg

Lars Christian Biilmann Rønn

Mark Throsby

Ole Baadsgaard

Simone De Haij

Thilo Riedl

Riemke Van Dijkhuizen Radersma

Isil Altintas

Frank Beurskens

Esther C W Breij

Margaret A Lindorfer

Marije Overdijk

Simone Oostindie

Patrick Engelberts

Hilma Van Der Horst

Martine E D Chamuleau

Tuna Mutis

Andreas Hollenstein

Ronald P Taylor

Kristel Kemper

Bart E C G De Goeij

Sjeng Horbach

Jaap Goudsmit

Esther Cornelia Wilhelmina Breij

Frank Everhardus Martinus Rebers

Jan Henrik Ter Meulen

Ugur Sahin

Friederike Gieseke

Alexander Muik

Sandra Verploegen

Christian Grunwitz

Jan H Ter Meulen

Louise Koopman

Ronald Taylor

Sieto Bosgra

Frederikke L Egerod

Tina Stummann

Rene M A Hoet

Ann-Louise Bergström

Kirstine Jacobsen

Rene M Hoet

Julia Boshuizen

Daniel Peeper

Henrik Jørn Ditzel

René Hoet

Simone Haij

CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.

Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof

The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

Agent, uses and methods for treatment

The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

Antibodies

The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

Humanized or chimeric CD3 antibodies

The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful correcting a deficient level progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.

Agents, uses and methods for the treatment of synucleinopathy

Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

Monoclonal antibodies against c-Met

Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.

Inert format

The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

Binding agents binding to PD-L1 and CD137 and use thereof

The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

Growing community of inventors

Halfweg, Netherlands

Edward Norbert Van Den Brink